Peginterferon and Lamivudine for Hepatitis B/DR. MARCELLIN REPLIES

Peginterferon and Lamivudine for Hepatitis B/DR. MARCELLIN REPLIES

TO THE EDITOR: Marcellin and colleagues (Sept. 16 issue)1 report that patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.1 HBeAg-negative chronic hepatitis B is usually associa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2004-12, Vol.351 (27), p.2879
Hauptverfasser: N Nimer Assy, Hussein, Osamah, Marcellin, Patrick
Format: Artikel
Sprache:eng
Schlagworte:
Hepatitis B
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 27
container_start_page 2879
container_title The New England journal of medicine
container_volume 351
creator N Nimer Assy
Hussein, Osamah
Marcellin, Patrick
description TO THE EDITOR: Marcellin and colleagues (Sept. 16 issue)1 report that patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.1 HBeAg-negative chronic hepatitis B is usually associated with precore mutations,2 but it may also develop in patients infected with wild-type strains, with mutations in the basic core promoter.3 Whether these two groups of patients with HBeAg-negative chronic hepatitis...
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_223934812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>792904371</sourcerecordid><originalsourceid>FETCH-proquest_journals_2239348123</originalsourceid><addsrcrecordid>eNqNik0PgiAAQFmrLfv4D6y7hUClxzSabtScdXdsYsMVGGC_vw79gN7lHd4bgSDaEhJSinZjECCE45DuEzIFM-c69CWiSQDSUt6V9tK20hoNhW4gF0_1HhqlJWyNhbnshVdeOZhujtUang9VxjgvLrBiJS_YdQEmrXg4ufx5DlYndsvysLfmNUjn684MVn9TjTFJCI0jTP6aPkWCOC0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223934812</pqid></control><display><type>article</type><title>Peginterferon and Lamivudine for Hepatitis B/DR. MARCELLIN REPLIES</title><source>New England Journal of Medicine Current</source><source>EZB Electronic Journals Library</source><creator>N Nimer Assy ; Hussein, Osamah ; Marcellin, Patrick</creator><creatorcontrib>N Nimer Assy ; Hussein, Osamah ; Marcellin, Patrick</creatorcontrib><description>TO THE EDITOR: Marcellin and colleagues (Sept. 16 issue)1 report that patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.1 HBeAg-negative chronic hepatitis B is usually associated with precore mutations,2 but it may also develop in patients infected with wild-type strains, with mutations in the basic core promoter.3 Whether these two groups of patients with HBeAg-negative chronic hepatitis...</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston: Massachusetts Medical Society</publisher><subject>Hepatitis B</subject><ispartof>The New England journal of medicine, 2004-12, Vol.351 (27), p.2879</ispartof><rights>Copyright © 2004 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>N Nimer Assy</creatorcontrib><creatorcontrib>Hussein, Osamah</creatorcontrib><creatorcontrib>Marcellin, Patrick</creatorcontrib><title>Peginterferon and Lamivudine for Hepatitis B/DR. MARCELLIN REPLIES</title><title>The New England journal of medicine</title><description>TO THE EDITOR: Marcellin and colleagues (Sept. 16 issue)1 report that patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.1 HBeAg-negative chronic hepatitis B is usually associated with precore mutations,2 but it may also develop in patients infected with wild-type strains, with mutations in the basic core promoter.3 Whether these two groups of patients with HBeAg-negative chronic hepatitis...</description><subject>Hepatitis B</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNik0PgiAAQFmrLfv4D6y7hUClxzSabtScdXdsYsMVGGC_vw79gN7lHd4bgSDaEhJSinZjECCE45DuEzIFM-c69CWiSQDSUt6V9tK20hoNhW4gF0_1HhqlJWyNhbnshVdeOZhujtUang9VxjgvLrBiJS_YdQEmrXg4ufx5DlYndsvysLfmNUjn684MVn9TjTFJCI0jTP6aPkWCOC0</recordid><startdate>20041230</startdate><enddate>20041230</enddate><creator>N Nimer Assy</creator><creator>Hussein, Osamah</creator><creator>Marcellin, Patrick</creator><general>Massachusetts Medical Society</general><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20041230</creationdate><title>Peginterferon and Lamivudine for Hepatitis B/DR. MARCELLIN REPLIES</title><author>N Nimer Assy ; Hussein, Osamah ; Marcellin, Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2239348123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Hepatitis B</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>N Nimer Assy</creatorcontrib><creatorcontrib>Hussein, Osamah</creatorcontrib><creatorcontrib>Marcellin, Patrick</creatorcontrib><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>N Nimer Assy</au><au>Hussein, Osamah</au><au>Marcellin, Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peginterferon and Lamivudine for Hepatitis B/DR. MARCELLIN REPLIES</atitle><jtitle>The New England journal of medicine</jtitle><date>2004-12-30</date><risdate>2004</risdate><volume>351</volume><issue>27</issue><spage>2879</spage><pages>2879-</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>TO THE EDITOR: Marcellin and colleagues (Sept. 16 issue)1 report that patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.1 HBeAg-negative chronic hepatitis B is usually associated with precore mutations,2 but it may also develop in patients infected with wild-type strains, with mutations in the basic core promoter.3 Whether these two groups of patients with HBeAg-negative chronic hepatitis...</abstract><cop>Boston</cop><pub>Massachusetts Medical Society</pub></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof The New England journal of medicine, 2004-12, Vol.351 (27), p.2879
issn 0028-4793
1533-4406
language eng
recordid cdi_proquest_journals_223934812
source New England Journal of Medicine Current; EZB Electronic Journals Library
subjects Hepatitis B
title Peginterferon and Lamivudine for Hepatitis B/DR. MARCELLIN REPLIES
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A31%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peginterferon%20and%20Lamivudine%20for%20Hepatitis%20B/DR.%20MARCELLIN%20REPLIES&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=N%20Nimer%20Assy&rft.date=2004-12-30&rft.volume=351&rft.issue=27&rft.spage=2879&rft.pages=2879-&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/&rft_dat=%3Cproquest%3E792904371%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223934812&rft_id=info:pmid/&rfr_iscdi=true